Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| §102 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMSELL, RILLA MARIE | 1 | 72.0% | +15.0% |
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| LANKFORD JR, LEON B | 1 | 69.9% | +31.3% |
| STEELE, AMBER D | 1 | 59.0% | +9.7% |
| MEJIAS, SAMANTHA LEE | 1 | 50.0% | +60.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568591 | FLUORESCENT PROBES | SAMSELL, RILLA MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269837 | NRF2-ACTIVATING COMPOUND | KIFLE, BRUCK | 14d |
| 18330510 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS | LANKFORD JR, LEON B | 54d |
| 18568591 | FLUORESCENT PROBES | SAMSELL, RILLA MARIE | — |
| 17605869 | EYE DISEASE MARKER | MEJIAS, SAMANTHA LEE | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1624 | 1 |
| 1657 | 1 |
| 1658 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18568591 | FLUORESCENT PROBES | SAMSELL, RILLA MARIE | 1653 | §101§103§112DP | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18269837 | NRF2-ACTIVATING COMPOUND | KIFLE, BRUCK | 1624 | §112 | Non-Final OA | 14d | Pending | Jun 27, 2023 |
| 18330510 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS | LANKFORD JR, LEON B | 1657 | §102 | Final Rejection | 54d | Pending | Jun 07, 2023 |
| 17610844 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE | STEELE, AMBER D | 1658 | DP | Final Rejection | 22d | Pending | Nov 12, 2021 |
| 17605869 | EYE DISEASE MARKER | MEJIAS, SAMANTHA LEE | 1618 | §103 | Non-Final OA | — | Pending | Oct 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial